BI-1701963 by Boehringer Ingelheim International for Metastatic Colorectal Cancer: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-1701963 overview
BI-1701963 is under development for the treatment of KRAS mutated advanced or metastatic solid tumors including lung adenocarcinoma, non-small cell lung cancer, metastatic pancreatic cancer, metastatic cholangiocarcinoma and metastatic colorectal cancer. It is administered through oral route as a film coated tablet. The drug candidate acts by targeting son of sevenless homolog 1 (SOS1).
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.
For a complete picture of BI-1701963’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
Source link
#BI1701963 #Boehringer #Ingelheim #International #Metastatic #Colorectal #Cancer #Likelihood #Approval